eLife: The Beginning of the End for the Journal Impact Factor?

$0.00

eLife’s Journal Impact Factor (JIF) eligibility expires next month. Support for the journal indicates the declining importance of the JIF as a standalone metric. This brave new world of transparency amid a multiplicity of metrics opens opportunities and challenges for metrics providers.

Read more on the Outsell Platform: eLife: The Beginning of the End for the Journal Impact Factor?

Author: Kate Worlock

Date: May 14, 2025

Healthcare’s Quantum Moment: The CAS/Cleveland Clinic Alliance

$0.00

CAS and Cleveland Clinic have partnered to accelerate drug discovery in brain health, combining IBM quantum computing capabilities with decades of innovation in scientific data. This alliance reflects CAS’s continued evolution from a trusted content provider to a leading force in healthcare AI.

Read more on the Outsell Platform: Healthcare’s Quantum Moment: The CAS/Cleveland Clinic Alliance

Author: Nick Scheponik

Date: April 29, 2025

CDP Consolidation Intensifies

$0.00

The customer data platform (CDP) space continues to consolidate as big agencies and enterprise software platforms buy in, niche players specialize, and the middle gets squeezed. Companies evaluating or using CDPs will need to monitor if their tool gets acquired and how things might change.

Read more on the Outsell Platform: CDP Consolidation Intensifies

Author: Randy Giusto

Date: April 15, 2025

Transforming Drug Discovery: The Impact of Siemens’ Acquisition of Dotmatics

$0.00

Siemens’ April 2025 acquisition of Dotmatics marks a decisive leap into the future of life sciences, blending data-driven drug discovery with industrial-scale automation. This move signals a shift toward an integrated, AI-powered ecosystem that is redefining pharmaceutical R&D and manufacturing.

Read more on the Outsell Platform: Transforming Drug Discovery: The Impact of Siemens’ Acquisition of Dotmatics

Author: Nick Scheponik

Date: April 08, 2025